Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Illumina : to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on Tuesday, January 31, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/17/2017 | 12:31pm CET

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2016 following the close of market on Tuesday, January 31, 2017.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, Marc Stapley, Executive Vice President and Chief Administrative Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, January 31, 2017. Interested parties may listen to the call by dialing 888.771.4371 (passcode: 44094804), or if outside North America by dialing +1.847.585.4405 (passcode: 44094804). Individuals may access the live teleconference in the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com.

A replay of the conference call will be available from 4:30 pm Pacific Time (7:30 pm Eastern Time) on January 31, 2017 through February 7, 2017 by dialing 888.843.7419 (passcode: 44094804), or if outside North America by dialing +1.630.652.3042 (passcode: 44094804).

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ILLUMINA, INC.
12:31p ILLUMINA : to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on ..
12:01p ILLUMINA, INC. : Lundin Law PC Announces Securities Class Action Lawsuit against..
01/16 ILLUMINA, INC. : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds ..
01/12 ILLUMINA, INC. : Khang & Khang LLP Announces Securities Class Action Lawsuit aga..
01/12 ILLUMINA : NRGene Collaborate to Accelerate Development of New Molecular Breedin..
01/11 ILLUMINA, INC. : Lundin Law PC Announces Securities Class Action Lawsuit against..
01/11 ILLUMINA INC : Results of Operations and Financial Condition, Amendments to Arti..
01/11 BIOTECH MOVERS : Illumina, Inc. (NASDAQ:ILMN) and EnteroMedics Inc (NASDAQ:ETRM)
01/11 IBM INTERNATIONAL BUSINESS MACHINES : IBM and Illumina Partner to Standardize G..
01/11 ILLUMINA, INC. : Khang & Khang LLP Announces Securities Class Action Lawsuit aga..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
01/08DJCorrection to Parkinson's Therapy Story
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
2016 EXCLUSIVE : U.S. regulator poised to approve Abbott purchase of St Jude - source..
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
01/11 BIOTECH FORUM DAILY DIGEST : Keytruda Continues To Power Merck; Revisiting Invit..
01/10 BIOTECH FORUM DAILY DIGEST : Biotech Continues To Rally. Revisiting Merrimack Ph..
01/10 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
01/10 Illumina up 15% premarket on launch single-cell gene sequencer
01/09 Illumina introduces new DNA sequencer that could enable a $100 genome
Advertisement
Financials ($)
Sales 2016 2 396 M
EBIT 2016 670 M
Net income 2016 438 M
Finance 2016 416 M
Yield 2016 -
P/E ratio 2016 54,79
P/E ratio 2017 49,62
EV / Sales 2016 9,79x
EV / Sales 2017 8,75x
Capitalization 23 882 M
More Financials
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 146 $
Spread / Average Target -10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Sam A. Samad Chief Financial Officer & Senior Vice President
Mostafa Ronaghi Chief Technology Officer & Senior Vice President
Norman Fjeldheim Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.26.97%23 882
THERMO FISHER SCIENTIF..3.68%57 788
DANAHER CORPORATION4.52%56 277
BOSTON SCIENTIFIC CORP..10.12%32 435
PHILIPS-1.83%28 197
INTUITIVE SURGICAL, IN..4.82%25 756
More Results